ArticleJournal of neuro-oncology2025
The oncogenic role of CCDC34 in lower-grade gliomas: prognostic significance and therapeutic potential.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the prognostic significance, molecular mechanisms, and therapeutic potential of CCDC34 in lower-grade gliomas (LGG).
methodsData from TCGA, CGGA, and GEO databases, comprising 1,064 LGG patient samples, were analyzed to evaluate the correlation between CCDC34 expression and clinical outcomes. Kaplan-Meier analysis, Cox regression, PPI, Virtual screening and meta-analysis were conducted to assess its prognostic significance. Mechanistic studies included DNA methylation analysis and KEGG pathway enrichment to explore regulatory mechanisms. In vitro and in vivo experiments were performed to validate its effects on tumor cell proliferation, migration, and tumorigenesis.
resultsElevated CCDC34 expression was significantly associated with advanced tumor grade, recurrence, and poor overall survival. Meta-analysis confirmed CCDC34 as an independent risk factor for prognosis. DNA methylation analysis revealed that CCDC34 expression is negatively regulated by cg19157696 methylation, with hypermethylation correlating with better patient outcomes. Pathway enrichment analyses showed that CCDC34 is involved in critical oncogenic pathways, including PI3K-Akt, HIF-1, and Notch, which promote tumor cell proliferation, invasion, and immune microenvironment modulation. It has also been found that five types of small-molecule drugs may have the potential to inhibit the expression of CCDC34. Functional validation demonstrated that silencing CCDC34 significantly reduced LGG cell proliferation, migration, and tumor formation in vitro and in vivo.
conclusionsCCDC34 acts as an oncogene in LGG and is strongly associated with poor prognosis and malignant progression. Its regulation via DNA methylation and involvement in key pathways highlight its potential as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.